tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Aug 3;8(3):E434.
doi: 10.3390/vaccines8030434.
Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine
Christopher E Lopez[SUP] 1 2 [/SUP], Kevin L Legge[SUP] 1 2 [/SUP]
Affiliations
Abstract
Influenza virus infections represent a serious public health threat and account for significant morbidity and mortality worldwide due to seasonal epidemics and periodic pandemics. Despite being an important countermeasure to combat influenza virus and being highly efficacious when matched to circulating influenza viruses, current preventative strategies of vaccination against influenza virus often provide incomplete protection due the continuous antigenic drift/shift of circulating strains of influenza virus. Prevention and control of influenza virus infection with vaccines is dependent on the host immune response induced by vaccination and the various vaccine platforms induce different components of the local and systemic immune response. This review focuses on the immune basis of current (inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV)) as well as novel vaccine platforms against influenza virus. Particular emphasis will be placed on how each platform induces cross-protection against heterologous influenza viruses, as well as how this immunity compares to and contrasts from the "gold standard" of immunity generated by natural influenza virus infection.
Keywords: T cells; adaptive immunity; antibody; influenza virus; vaccine.
. 2020 Aug 3;8(3):E434.
doi: 10.3390/vaccines8030434.
Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine
Christopher E Lopez[SUP] 1 2 [/SUP], Kevin L Legge[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32756443
- DOI: 10.3390/vaccines8030434
Abstract
Influenza virus infections represent a serious public health threat and account for significant morbidity and mortality worldwide due to seasonal epidemics and periodic pandemics. Despite being an important countermeasure to combat influenza virus and being highly efficacious when matched to circulating influenza viruses, current preventative strategies of vaccination against influenza virus often provide incomplete protection due the continuous antigenic drift/shift of circulating strains of influenza virus. Prevention and control of influenza virus infection with vaccines is dependent on the host immune response induced by vaccination and the various vaccine platforms induce different components of the local and systemic immune response. This review focuses on the immune basis of current (inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV)) as well as novel vaccine platforms against influenza virus. Particular emphasis will be placed on how each platform induces cross-protection against heterologous influenza viruses, as well as how this immunity compares to and contrasts from the "gold standard" of immunity generated by natural influenza virus infection.
Keywords: T cells; adaptive immunity; antibody; influenza virus; vaccine.